ACTR-06. CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: HALF-WAY REPORT

Approximately 60% of glioblastoma multiforme (GBM) patients possess an unmethylated methylguanine DNA-methyltransferase (MGMT gene, which confers a limited response to standard of care treatment with temozolomide (TMZ) resulting in a lower survival. VAL-083 is a novel bi-functional DNA targeting age...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Chen, Zhong-ping, Guo, Chengcheng, Yang, Qun-ying, Li, Jia-wei, Wu, Shao-xiong, Bacha, Jeffrey, Johnson, Gregory, Langlands, John, Kwan, Claire, Kanekal, Sarath, Schwartz, Richard, Lopez, Lorena, Brown, Dennis
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials - Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847153/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.050
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados